Braftovi (encorafenib capsules − Array) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has recurrent, advanced, or metastatic disease
• Patient has BRAF V600E mutation-positive disease
• The medication will be taken in combination with Mektovi (binimetinib tablets)

Approval duration

1 year